Pancreatic Cancer Pathway

specific

Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways. Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act

1

Centers

0

Active Trials

$115K

Cancer Funding

Top Centers for Pancreatic Cancer Pathway(1)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Clinical
High-Volume Research Center
100.0

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →